Drug profile

The FDA adverse-event record for Danofloxacin Mesylate

47 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Danofloxacin Mesylate. See the species affected, top reactions, and outcomes below.

47
adverse-event reports
57.4%
death-coded share
Cattle
most-reported species
22
Death - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
47
Total Reports
27
Deaths Reported
57.4%
Death Rate

Active Ingredients

Danofloxacin Mesylate

Administration Routes

SubcutaneousUnknownTopicalIntramuscularIntravenousOther

Species Affected

Cattle 36
Unknown 8
Human 2
Dog 1

Most Affected Breeds

Cattle (other) 17
Mixed (Cattle) 15
Unknown 10
Aberdeen Angus 2
Cattle (unknown) 1
Crossbred Bovine/Cattle 1
Black Mouth Cur 1

Most Reported Reactions

Death 22
Lack of efficacy (bacteria) - NOS 13
Lack of efficacy - NOS 12
Unclassifiable adverse event 4
Necropsy performed 4
Uncoded sign 3
Malaise 3
Anaphylaxis 2
Accidental exposure 2
Incorrect route of drug administration 2
Lameness 2
Drug dose administration interval too long 2

Outcome Breakdown

Died
26 (40.6%)
Outcome Unknown
23 (35.9%)
Recovered/Normal
7 (10.9%)
Ongoing
4 (6.3%)
Recovered with Sequela
3 (4.7%)
Euthanized
1 (1.6%)

Danofloxacin Mesylate Adverse Event Insights

47 reports name Danofloxacin Mesylate; 27 recorded a death outcome (57.4% of reported events, not a population-level mortality rate). Active ingredient: Danofloxacin Mesylate. Administration routes: Subcutaneous, Unknown, Topical, Intramuscular.

By species: Cattle (36 reports), Unknown (8 reports), Human (2 reports). By breed: Cattle (other) (17), Mixed (Cattle) (15), Unknown (10).

Leading clinical signs: Death (22), Lack of efficacy (bacteria) - NOS (13), Lack of efficacy - NOS (12), Unclassifiable adverse event (4). Outcome, 64 coded reports: Died leads at 40.6%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.